Access to new treatments for cancer is a matter of money. Without third party payment
most patients cannot afford the new medicines. Decisions by agencies such as NICE
must therefore be critically reviewed and debated. Mason and Drummond’s study in this
issue
1
provides an important insight into NICE’s decisions on cancer drugs. They conclude
that the rejection rate has increased over time, and relate this to the change in
the appraisal methods in August 2006, and to changing evidence on cost-effectiveness.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Mason AR, Drummond MF. Public funding of new cancer drugs: Is NICE getting nastier? Eur J Cancer [in this issue].
Appraising life-extending, end of life treatments. <http://www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf> [accessed 22 January].
Wilking N, Jönsson B, Högberg D. Comparator report on patient access to cancer drugs in Europe. 15 January 2009 <www.comparatorreports.se>.
Article info
Publication history
Published online: March 06, 2009
Accepted:
January 28,
2009
Received:
January 20,
2009
Identification
Copyright
© 2009 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.
